VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics (VRDN) hits USD 22.82, trading near its 200‑day SMA of 21.99. Explore its market cap, YTD gain, and peer performance insights.

Viridian Therapeutics shares rise 2.6% as investors eye its promising thyroid eye disease pipeline and potential partnership deals, offering a cautious biotech upside.

Viridian Therapeutics jumps 7.84% to $23.05 as investor confidence spikes over its thyroid eye disease pipeline and growing market momentum.